Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHYSIOLOGICAL-EFFECTS OF SLOW-RELEASE POTASSIUM PHOSPHATE FOR ABSORPTIVE HYPERCALCIURIA - A RANDOMIZED DOUBLE-BLIND TRIAL
Autore:
BRESLAU NA; HELLER HJ; REZAALBARRAN AA; PAK CYC;
Indirizzi:
BAYLOR UNIV,MED CTR,3801 GASTON 204 DALLAS TX 75246 UNIV TEXAS,SW MED CTR,CTR MINERAL METAB & CLIN RES DALLAS TX 00000
Titolo Testata:
The Journal of urology
fascicolo: 3, volume: 160, anno: 1998,
parte:, 1
pagine: 664 - 668
SICI:
0022-5347(1998)160:3<664:POSPPF>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
PRIMARY HYPERPARATHYROIDISM; CALCIUM; 1,25-DIHYDROXYVITAMIN-D; THERAPY; EXCRETION; NEPHROLITHIASIS; HUMANS;
Keywords:
DELAYED-ACTION PREPARATIONS; PHOSPHATES; CALCIUM; URINARY CALCULI; RANDOMIZED CONTROLLED TRIALS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
N.A. Breslau et al., "PHYSIOLOGICAL-EFFECTS OF SLOW-RELEASE POTASSIUM PHOSPHATE FOR ABSORPTIVE HYPERCALCIURIA - A RANDOMIZED DOUBLE-BLIND TRIAL", The Journal of urology, 160(3), 1998, pp. 664-668

Abstract

Purpose: We examined the physiological effects and tolerance of UroPhos-K,parallel to a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 +/- 72 to 166 +/- 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 +/- 11 to 42 +/- 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover alsodecreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinalabsorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/05/20 alle ore 23:33:08